In a double-blind, randomized, placebo-controlled 3-week study
evaluating ProAir RespiClick® in 184 pediatric patients (ages 4-11)
with asthma, ProAir RespiClick® had efficacy greater than placebo.1
The efficacy of ProAir RespiClick® was assessed in a 3-week, randomized, double-blind, placebo-controlled study. After a 2-week run-in period, treatment was administered for 3 weeks, with a follow-up after 3 weeks. Children ages 4 to 11 (n=184, with 92 in each arm) were randomly assigned to receive ProAir RespiClick® at a dose of 180 mcg or placebo inhaler, four times daily.
Day 1: Significantly greater FEV1 with ProAir RespiClick®1
Increases in baseline-adjusted FEV1 up to 6 hours (AUC0-6hr) were significantly greater for ProAir
RespiClick® than for placebo at Day 1.
Day 22: Significantly greater FEV1 with ProAir RespiClick®1
Increases in baseline-adjusted FEV1 up to 6 hours (AUC0-6hr) were significantly greater for ProAir RespiClick® than for placebo at Day 22.
In a double-blind, randomized, placebo-controlled, single-dose crossover study evaluating ProAir RespiClick® and the leading rescue metered-dose inhaler in 71 adult and adolescent patients,12 years of age and older with persistent asthma, ProAir RespiClick® had efficacy greater than placebo.2
In two replicate 12-week, randomized, double-blind, placebo-controlled trials, ProAir RespiClick®
(n=153) was compared with placebo (n=163) in asthmatic patients 12 to 76 years of age at a dose of
180 mcg albuterol 4 times daily.
Study 1: Significantly greater FEV1 with ProAir RespiClick®2
Increases in baseline-adjusted FEV1 up to 6 hours (AUC0-6hr) were
significantly greater (P<0.0001) for ProAir RespiClick® than for placebo in Study 1.
Study 2: Significantly greater FEV1 with ProAir RespiClick®2
Increases in baseline-adjusted FEV1 up to 6 hours (AUC0-6hr) were
significantly greater (P<0.0001) for ProAir RespiClick® than for placebo in Study 2.